Modern Strategy for Preclinical Pharmaceutical R&D: Towards the Virtual Research Company - Couverture rigide

Cavalla, David

Couverture rigide

ISBN 10 : 0471971170 ISBN 13 : 9780471971177

Editeur : Wiley, 1997

Synopsis

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.

A propos du livre

À propos de l'auteur

David Cavalla is an expert on secondary uses for existing drugs, or drug repurposing. He currrently operates through his consultancy, Numedicus Ltd, having worked in drug repurposing for 15 years. Previously he was CEO of Arachnova, and prior to that held various senior positions in pharmaceutical drug discovery at GSK and Napp Research Centre. He has written widely on drug discovery strategy, and is the author of 70 published papers and patents.

Détails de l'édition

• Éditeur: Wiley
• Date d'édition: 1997
• Langue: anglais
• ISBN 10: 0471971170
• ISBN 13: 9780471971177
• Reliure: Relié
• Nombre de pages: 231
• Coordonnées du fabricant: non disponible
• Personne responsable: Wiley-VCH GmbH; product_safety@wiley.com; ; Boschstrasse 12; Weinheim; 69469; Allemagne